| Inclusion Criteria: | 1) Patients can be as old as 70 years.
2) They must have a diagnosis of MCL, either (1) Recurrent, (2) Newly diagnosed (after cytoreduction with conventional chemotherapy) but with high-risk features (blastic or blastoid features, leukemic phase, or elevated B^2 microglobulin (> 3).
3) Patients that have received prior conventional chemotherapy but have not achived CR.
4) Disease must be chemosensitive, (ie, patients must not have had a partial response to prior therapy).
5) Patients whose disease failed to respond to a previous autologous transplantation may also be eligible.
6) Patients must have a matched or 1 antigen mismatched sibling or unrelated donor.
7) PS </= 2.
8) Inclusion criteria for Immunomodulation Post transplantation: Patients can be as old as 70 years. Patients must have a diagnosis of MCL or CLL with one of the following characteristics: 1. Patients who develop disease progression or do not experience a CR within 3 months post-allogeneic transplantation 2. Patients with a weak chimerism (any mixed chimerism of donor T cells in patients receiving Campath by day 90, and less than 20% for patients not receiving Campath) or a drop of 20% or more with an amount of donor cells present in the blood < 50% by PCR .
9) Continued from Inclusion # 8: Patients must have the same donor of the original transplant willing to donate lymphocytes. 4. PS </ 2. |